Glenmark Pharma receives ANDA approval for Abiraterone Acetate tablets USP, 500 mg

The tablets are a generic version of Zytiga Tablets, 500 mg, of Janssen Biotech

Glenmark Pharma has received final approval by the US Food and Drug Administration (FDA) for Abiraterone Acetate Tablets USP, 500 mg, the generic version of Zytiga Tablets, 500 mg, of Janssen Biotech, the company informed via a statement.

According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately $260.2 million.

Abiraterone Acetate TabletsANDA approvalGlenmark PharmaJanssen BiotechUS FDA approval
Comments (0)
Add Comment